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Materials and Methods
Genetic analysis of PINK1. PCR reactions were performed in 25µl containing 1x PCR buffer, 1.5mM MgCl 2 , 200µM of each dNTP, 0.3µM of both forward and reverse primers, 1.5 U AmpliTaq Gold DNA polymerase (Applied Biosystems, Warrington, UK) and 50ng of genomic DNA. Cycle conditions were: 11 min at 94°C; 30 cycles of 30s denaturation at 94°C, 30s annealing, and 90s extension at 72°C; final extension 7 min at 72°C (Primers sequences are given in Table S1 ). Bidirectional sequencing was performed using Big Dye
Terminator v3.1 (Applied Biosystems, Warrington, UK) and electrophoresed on an ABI 3100 automated sequencer.
PINK1 cDNA was synthesized using SuperScript (Invitrogen, Paisley, UK) amplified using PINK1 cDNA: fw-I 5'-CCA AGT TTG TTG TGA CCG GC-3', rv-I 5'-CTT CAT AAC GAG GAA CAG CGT CC-3', fw-II 5'-ATC CAA GAG AGG TCC CAA GCA AC-3', rv-II 5'-AGT AAT TCA CCA GCT CCA TGC A-3'. PCR conditions were as above, with annealing temperature of 63°C for 35 cycles.
Bioinformatics of PINK1 protein. Multiple sequence alignments were produced with
ClustalW software at the European Bioinformatics Institute (http://www2.ebi.ac.uk/clustalw). The mitochondrial targeting motif was predicted by using Mitoprot-2 (http://ihg.gsf.de/ihg/mitoprot.html) (mitochondrial score >99.8%).
The kinase domain was predicted using the following dedicated software: SMART (http://smart.embl-heidelberg.de/), Prodom (http://prodes.toulouse.inra.fr/prodom/current/html/home.php) and PFAM (http://pfam.wustl.edu/).
Constructs for mammalian cell expression. Full-length PINK1 cDNAs were amplified using the primers hPINK1 (5'-ggcggatccatggcggtgcgacaggcg-3') and hPINK2 (5'-ctcgaattcgggacatcacagggctgc-3') and cloned into the BamHI and EcoRI sites of the vector pRK5myc. The expressed PINK1 protein had a c-myc epitope tag attached to the Nterminus. The G309D mutation was introduced into pRK5-myc-PINK1 using the Probes, Leiden, Netherlands) for 1 hour in a humidified 5% CO2 atmosphere at 37°C prior to fixing. Standard immunofluorescence was performed using a Zeiss Axioskop 2 plus microscope and digital images were captured using a Zeiss Axiocam camera and processed in Adobe Photoshop (S1). Negative controls omitting primary antibody separately or in combination with mitotracker was performed and no significant staining was observed.
Western blot assays. COS-7 cells were transfected as described above. Cells were harvested 48 hours after transfection and lysed in RIPA buffer (50mM Tris, 150mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate) containing protease inhibitors (complete mini protease inhibitor cocktail, Roche, Lewes, UK). Protein concentrations in all lysates were determined using a bicinchoninic acid ( Experiments were performed in triplicate and results reported are an average of four independent experiments. Statistical analysis was performed using one way ANOVA.
SOM text Clinical Phenotype
The clinical phenotype resembles sporadic or idiopathic PD (IPD), although the age at onset was earlier, usually in the fourth-fifth decade (range 24-48 years) compared to IPD where the average age of onset is 60-70 years (S4). Disease progression was slower than in IPD and sustained response to L-dopa and occurrence of L-dopa associated dyskinesias of variable severity were observed. Distinguishing clinical features, such as dystonia at onset, sleep benefit and psychiatric disturbances, were rarely reported in PINK1 mutated patients.
Clinical Samples
Mitochondrial dysfunction in idiopathic PD has previously been associated with Complex I deficiency. We were unable to determine Complex I activity in the PARK6 families due to a lack of suitable clinical material.
PINK1 variants
The following PINK1 polymorphisms were found in control individuals: Table S2 . PCR-amplification conditions for PINK1 exons
